Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Neurocrine Biosciences Comprehensive Income (Loss), Net of Tax, Attributable to Parent increased by 20.6% to $185.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1568.5%, from $11.10M to $185.20M. Over 3 years (FY 2022 to FY 2025), Comprehensive Income (Loss), Net of Tax, Attributable to Parent shows an upward trend with a 48.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher values indicate stronger overall financial performance and equity growth for the parent company.
Detailed definition
This represents the total comprehensive income or loss attributable specifically to the parent company's shareholders af...
Peer comparison
Standard financial reporting metric used by all public companies to show total equity changes.
other_comprehensive_income_net_of_taxHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $42.00M | $22.20M | $6.30M | -$19.80M | $66.70M | $95.10M | -$71.40M | $97.10M | $82.50M | $156.40M | $39.70M | $64.20M | $141.80M | $94.40M | $11.10M | $111.00M | $210.20M | $153.60M | $185.20M |
| QoQ Change | — | -47.1% | -71.6% | -414.3% | +436.9% | +42.6% | -175.1% | +236.0% | -15.0% | +89.6% | -74.6% | +61.7% | +120.9% | -33.4% | -88.2% | +900.0% | +89.4% | -26.9% | +20.6% |
| YoY Change | — | — | — | -147.1% | +200.5% | — | <-999% | +590.4% | +23.7% | +64.5% | +155.6% | -33.9% | +71.9% | -39.6% | -72.0% | +72.9% | +48.2% | +62.7% | >999% |
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's comprehensive income (loss), net of tax, attributable to parent?
- Neurocrine Biosciences (NBIX) reported comprehensive income (loss), net of tax, attributable to parent of $185.20M in Q1 2026.
- How has Neurocrine Biosciences's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Neurocrine Biosciences's comprehensive income (loss), net of tax, attributable to parent increased by 1568.5% year-over-year, from $11.10M to $185.20M.
- What is the long-term trend for Neurocrine Biosciences's comprehensive income (loss), net of tax, attributable to parent?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's comprehensive income (loss), net of tax, attributable to parent has grown at a 48.5% compound annual growth rate (CAGR), from $148.30M to $485.90M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- The total comprehensive profit or loss belonging to the parent company's shareholders.